Ad26COVS1

A viral vector vaccine designed against SARS-CoV-2 developed by Johnson & Johnson. Its vector encodes the SARS-CoV-2 Spike protein.

Also Known As:

Ad26.COV2.S; JNJ 78436735; JNJ-78436735; COVID 19 Vaccine Johnson & Johnson; JNJ78436735; Johnson & Johnson Covid 19 Vaccine; COVID-19 Vaccine Johnson & Johnson; Johnson & Johnson Covid-19 Vaccine

Networked: 264 relevant articles (21 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        Ad26COVS1: 264

Experts

1.	Schuitemaker, Hanneke: 12 articles (04/2022 - 01/2021)
2.	Barouch, Dan H: 11 articles (01/2022 - 01/2021)
3.	Douoguih, Macaya: 10 articles (04/2022 - 01/2021)
4.	Sadoff, Jerald: 10 articles (04/2022 - 01/2021)
5.	Struyf, Frank: 8 articles (04/2022 - 01/2021)
6.	Le Gars, Mathieu: 7 articles (01/2022 - 01/2021)
7.	McMahan, Katherine: 7 articles (01/2022 - 01/2021)
8.	Yu, Jingyou: 7 articles (01/2022 - 01/2021)
9.	Gray, Glenda: 6 articles (08/2022 - 10/2021)
10.	Liu, Jinyan: 6 articles (01/2022 - 01/2021)

Related Diseases

1.	COVID-19 10/01/2021 - "A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitalization and death. " 01/01/2022 - "A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe-critical Covid-19. " 01/01/2022 - "These data provide insights into the molecular mechanisms of Ad26.COV2.S protection against severe COVID-19 in animal models." 04/01/2022 - "The objective of this study was to report the first case of Guillain-Barré following the COVID-19 vaccination with the Johnson & Johnson COVID-19 vaccine. " 08/12/2023 - "Here we examine the effect of prior SARS-CoV-2 infection on the magnitude and phenotype of the memory B cell response to single dose Johnson and Johnson (Ad26.COV2.S) vaccination in South African health care workers. "
2.	Breakthrough Infections 01/01/2022 - "Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection." 08/06/2021 - "The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants." 01/01/2022 - "The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants." 01/01/2022 - "Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern." 01/01/2022 - "Vaccination with Ad26.COV2.S (HR1.54, 95%CI 1.52-1.56) or ChAdOx1 (HR1.68, 95%CI 1.66-1.69) was associated with a higher risk of a breakthrough infection compared to BNT162b2, while mRNA-1273 was associated with a lower risk (HR0.68, 95%CI 0.67-0.69). "
3.	Thrombocytopenia (Thrombopenia) 01/01/2022 - "The risk of CVST with thrombocytopenia was slightly increased in patients receiving Ad26.COV2.S compared with the estimated background risk. " 01/01/2021 - "Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer." 01/01/2021 - "Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination." 01/01/2021 - "The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. " 01/01/2023 - "There were 34 cases of co-occurring thrombosis with thrombocytopenia in Ad26.COV2.S recipients (46 per 100,000 person-years) and 15 after placebo (75 per 100,000 person-years) in clinical trials. "
4.	Infections 01/01/2022 - "Thus, in this study, using an Ad26.CoV2.S dose-down approach in nonhuman primates (NHPs), the role of neutralization, Fc effector function, and T-cell immunity were collectively probed against infection as well as against viral control. " 11/01/2023 - "Importantly, an Ad26.COV2.S booster dose increased the magnitude of the antibody response in individuals with no prior infection to similar levels as those with previous infection. " 03/15/2023 - "Importantly, an Ad26.COV2.S booster dose increased the magnitude of the antibody response in individuals with no prior infection to similar levels as those with previous infection. " 09/03/2022 - "Relative to the baseline, stable protection was observed for Ad26.COV2.S against infections (OR [95% confidence interval (CI)], 1.31 [1.18-1.47]) and hospitalizations (OR [95% CI], 1.25 [0.86-1.80]). " 01/01/2022 - "Similarly, immunization of 129S2 mice and Syrian hamsters with a high dose of Ad26.COV2.S reduced lung infection after B.1.621 virus challenge. "
5.	Intracranial Sinus Thrombosis (Sinus Thrombosis) 07/04/2022 - "As of 31 August 2021, in the United States, 54 cases of VITT following Ad26.COV2.S vaccination (37 female, 17 male) have been reported out of 14.1 million total shots given, 29 of which had cerebral venous sinus thrombosis (CVST). " 01/01/2022 - "Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination." 01/01/2021 - "US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021." 01/01/2022 - "Twelve cases of cerebral venous sinus thrombosis after vaccination with the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson) have previously been described. " 04/01/2022 - "Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject."

Related Drugs and Biologics

1.	Vaccines
2.	2019-nCoV Vaccine mRNA-1273
3.	BNT162 Vaccine
4.	Neutralizing Antibodies
5.	ChAdOx1 nCoV-19
6.	sinovac COVID-19 vaccine
7.	Proteins (Proteins, Gene)
8.	Immunoglobulin G (IgG)
9.	Messenger RNA (mRNA)
10.	CI 22

Related Therapies and Procedures

1.	Renal Replacement Therapy (Therapies, Renal Replacement)
2.	Thrombectomy
3.	Critical Care (Surgical Intensive Care)
4.	Therapeutics
5.	Injections